CD8A and neoplasm: The promise of the use of DCs transfers appears obvious; it focuses on another cell type in addition to the professional killers of CD8 and NK cells, thus increasing the diversity of lytic mechanisms as well as the diversity of tumor cell recognition mechanisms (12, 13).